The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) closed at $483.04 up 1.70% from its previous closing price of $474.95. In other words, the price has increased by $1.70 from its previous closing price. On the day, 1.19 million shares were traded. VRTX stock price reached its highest trading level at $484.45 during the session, while it also had its lowest trading level at $474.16.
Ratios:
For a deeper understanding of Vertex Pharmaceuticals, Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.53. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $515.
Evercore ISI Downgraded its Outperform to In-line on February 06, 2024, whereas the target price for the stock was revised from $436 to $438.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 03 ’24 when WAGNER CHARLES F JR sold 3,250 shares for $460.00 per share. The transaction valued at 1,495,000 led to the insider holds 47,137 shares of the business.
Tatsis Ourania sold 2,175 shares of VRTX for $1,000,500 on Jun 03 ’24. The EVP, Chief Reg. & Quality Off. now owns 49,098 shares after completing the transaction at $460.00 per share. On May 31 ’24, another insider, Tatsis Ourania, who serves as the EVP, Chief Reg. & Quality Off. of the company, sold 2,250 shares for $445.00 each. As a result, the insider received 1,001,250 and left with 51,273 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 124649922560 and an Enterprise Value of 115200106496. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.34, and their Forward P/E ratio for the next fiscal year is 26.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.25 while its Price-to-Book (P/B) ratio in mrq is 6.73. Its current Enterprise Value per Revenue stands at 11.311 whereas that against EBITDA is 25.133.
Stock Price History:
Over the past 52 weeks, VRTX has reached a high of $477.31, while it has fallen to a 52-week low of $323.02. The 50-Day Moving Average of the stock is 15.46%, while the 200-Day Moving Average is calculated to be 22.61%.
Shares Statistics:
For the past three months, VRTX has traded an average of 1.08M shares per day and 1365460 over the past ten days. A total of 257.70M shares are outstanding, with a floating share count of 257.35M. Insiders hold about 0.27% of the company’s shares, while institutions hold 92.81% stake in the company. Shares short for VRTX as of 1715731200 were 3769903 with a Short Ratio of 3.51, compared to 1713139200 on 4029234. Therefore, it implies a Short% of Shares Outstanding of 3769903 and a Short% of Float of 1.46.
